Clin2
NCT07698548Possibly a fitNot yet recruiting

Herbal medicine plus HIV treatment for low CD4

HIV-1 InfectionAcquired Immunodeficiency SyndromeImmune Reconstitution FailureImmunological Non-responderSpleen-Kidney Yang Deficiency Syndrome

Treatments studied

Part of Immune system & allergy, Infections clinical trials.

This trial tests if adding a Chinese herbal medicine (Fuyang Jiedu Granules) to your regular HIV treatment can help raise your CD4 count. It's for people whose CD4 count stays low even after years of successful HIV treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
240 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You are between 18 and 60 years old.
  • You have been on HIV treatment (ART) for more than 4 years.
  • Your viral load has been undetectable (below 50 copies/mL) for more than 3 years.
  • Your CD4 count is still low (below 350 cells per microliter) despite treatment.
  • You have been diagnosed with a Traditional Chinese Medicine pattern called 'spleen-kidney yang deficiency' (which may include symptoms like fatigue, feeling cold, loose stools, or lower back pain).
  • You are willing to take the study medication (Fuyang Jiedu Granules) along with your regular HIV treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07698574Not yet recruiting
Qiling Yiqi Tablets for HIV immune non-responders

This study tests if adding Qiling Yiqi Tablets (a Chinese herb formula) to your usual HIV medications can help people whose immune system hasn't fully recovered despite having undetectable HIV. It is for people with a specific TCM diagnosis called lung-spleen qi deficiency.

Beijing, Beijing Municipality
NCT07719491Not yet recruiting· Phase 1
Study of GS-0415 for People Living with HIV

This trial tests a new medicine, GS-0415, for people with HIV who are already on a stable treatment plan. It aims to see how safe and effective the new medicine is.

NCT07081763Not yet recruiting· Phase 2
Immune therapy for stopping HIV treatment safely

This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.

NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments

This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.

Seattle, Washington
NCT07637877Recruiting· Phase 2
New Treatments for HIV Patients With Low Immune Cell Counts

This study tests targeted therapies to help HIV patients whose immune systems haven't fully recovered despite years of successful HIV medication. You may qualify if your CD4 count (a measure of immune health) stays low even though your viral load is undetectable.

Beijing, Beijing Municipality
NCT07579741Recruiting· Phase 1/Phase 2
Testing JL18008 for HIV Patients Not Recovering Immune Cells

This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.

Beijing, Beijing Municipality

Hear when a new HIV-1-infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.